Restarting subcutaneous infliximab 240 mg after treatment interruption of at least 16 weeks was able to recapture response ...
The FDA has approved Saphnelo (anifrolumab-fnia) for subcutaneous administration in patients with systemic lupus ...
Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...
Eight deaths linked to the administration of vitamin IV infusions in Hermosillo, Sonora, Mexico have now been confirmed, along with three additional people affected—one hospitalized and two discharged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results